Revolution Medicines announced that Mark A. Goldsmith, in his role as CEO and Chairman, stated on July 23, 2025, that encouraging clinical data demonstrated therapeutic potential for elironrasib.
1 report, 1 independent
Updated Jul 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Revolution Medicines announced that Mark A. Goldsmith, in his role as CEO and Chairman, stated on July 23, 2025, that encouraging clinical data demonstrated therapeutic potential for elironrasib.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Revolution Medicines (United States)
company in Redwood City, United States
Nothing else this week.
-
Mark A. Goldsmith
American judge
Nothing else this week.
- FDA
Related events
- daraxonrasib received Breakthrough Therapy Designation from the FDA for metastatic pancreatic ductal adenocarcinoma.
- Cogent Biosciences plans to submit an NDA to the FDA, with Andrew Robbins as President and CEO.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
Coverage
Newest first; wire copies grouped- GlobeNewswireRevolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated